Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexeo Therapeutics, Inc. (LXEO) Preferred Stock Liabilities (2022 - 2023)

Lexeo Therapeutics' Preferred Stock Liabilities history spans 2 years, with the latest figure at $85.3 million for Q3 2023.

  • For Q3 2023, Preferred Stock Liabilities fell 53.92% year-over-year to $85.3 million; the TTM value through Sep 2023 reached $85.3 million, down 53.92%, while the annual FY2022 figure was $185.0 million, N/A changed from the prior year.
  • Preferred Stock Liabilities for Q3 2023 was $85.3 million at Lexeo Therapeutics, down from $185.0 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $185.0 million in Q3 2022 and bottomed at $85.3 million in Q3 2023.